
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): December 5, 2005

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Virginia
(State or Other Jurisdiction
of Incorporation)

001-13467
(Commission File Number)

56-1641133
(IRS Employer
Identification No.)

601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)

Registrant's telephone number, including area code: **(804) 648-3820**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 8.01 OTHER EVENTS.

As of December 5, 2005, Commonwealth Biotechnologies, Inc. ("CBI") entered into a Joint Marketing Agreement with Intertek ASG, an operating business unit of Intertek Group PLC. The Agreement will co-promote services to the Life Sciences Industry with international focus.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a) Financial statements of businesses acquired.

Not Applicable.

(b) Pro forma financial information.

Not Applicable.

(c) Exhibits.

99.1 Press release, dated December 5, 2005, announcing the launch of a global marketing arrangement between CBI and Intertek ASG.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMONWEALTH BIOTECHNOLOGIES, INC.

By: /s/ Robert B. Harris, Ph.D.

Robert B. Harris, Ph.D.
President and Chief Executive Officer

Dated: December 6, 2005

EXHIBIT INDEX

Number	Description of Exhibit
99.1	Press release, dated December 5, 2005, announcing the launch of a global marketing arrangement between CBI and Intertek ASG.

For further Information contact:
Robert B Harris, Ph.D.
President/CEO
Commonwealth Biotechnologies, Inc.
804-648-3820

**Commonwealth Biotechnologies, Inc. and Intertek ASG Launch Global
Marketing Agreement**

Companies will Co-Promote Services to the Life Sciences Industry with International Focus

RICHMOND, VA., December 5, 2005 — Commonwealth Biotechnologies, Inc. (NASDAQ Capital Market: CBTE) and Intertek ASG, an operating business unit of Intertek Group plc (LSE:ITRK), have concluded a joint marketing agreement to co-promote services to the Life Sciences Industry. The agreement will provide for ready access of customers to the combined capabilities of the two organizations, and enable better overall solutions to be developed on the demanding timescales required by clients in the Life Sciences Industry. The broad geographic reach brought about by this partnership will offer a new solution for multinational companies with global service requirements.

“This is one of those true win-win relationships where each company stands to benefit enormously from the added technology offerings and extended global reach. In the past, CBI has made forays into the global market, especially the European markets, with only limited success. The major barrier has always been lack of a physical presence or a bona fide partnering arrangement. By partnering with Intertek ASG, that barrier will be removed,” said Richard J. Freer, Chairman & COO of CBI.

“Here at Intertek ASG, we have been excited by the range and quality of technical skills and capabilities available within CBI, and we believe that these complementary offerings will be of great interest to our customers in this industry. Intertek has an excellent global network of facilities and through this partnership we believe we will be

able to deliver effective new services with companies seeking the specialist skills accessible through this combined offering,” said John Conti-Ramsden, Managing Director of Intertek ASG.

Intertek ASG is based in Manchester, UK and provides comprehensive laboratory services in chemical analysis for Pharmaceutical, Biotechnology and Specialty Chemical companies. These services include multi-faceted offerings for complex characterization, problem solving, regulatory analysis and combined regulatory packages to support product development and manufacture. The laboratory is GLP registered with the MHRA, and also has cGMP compliant systems, enabling support to clients at all stages of the development pipeline. Intertek ASG is part of Intertek Group plc, a leading testing, inspection, outsourcing and certification organization, assessing customers’ products and commodities against a wide range of quality, safety, regulatory and performance standards, and certifies the management systems of customers. The Intertek Group operates 300 laboratories and employs 14,500 people around the world. <http://www.intertek.com>

Commonwealth Biotechnologies, Inc. is a solutions provider to the global biotechnology industry, academic institutions, government agencies, and pharmaceutical companies. It offers broad ranging expertise and a complete array of the most current analytical and synthetic chemistries and biophysical analysis technologies, many of which are not available from other commercial sources. CBI has crafted a stimulating, open environment where scientists collaborate among themselves and with our clients, take on interesting challenges and develop creative solutions. Through its FIL division, CBI offers comprehensive genetic identity testing, including paternity, forensic, and CODIS analyses. CBI is accredited by the American Association of Blood Banks, CLIA, and the National Forensic Science Technology Council, and operates fully accredited BSL-3 laboratory.

#

Founded in 1992, CBI is located in Gateway Centre, Chesterfield County at 601 Biotech Drive, 23235 (1-800-735-9224). For more information, visit CBI on the web at www.cbi-biotech.com and visit FIL at www.fairfaxidlab.com.

Intertek is dedicated to Customer Service. Please visit Intetek on the web at www.intertek-cb.com

#

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in CBI's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Readers are cautioned not to place undo reliance on these forward-looking statements, which speak only as the date hereof. Specifically, CBI cannot guarantee that the agreement executed with Intertek ASG will produce any revenues or new business prospects. CBI undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.